Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.
Lead Product(s): TLC-2716
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrsoBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2022